Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Mona Lisa Touch Clinical Outcomes Registry

16. november 2026 oppdatert av: Clarendon Health

Long-term Outcomes Following Mona Lisa Touch Fractional CO₂ Laser Treatment for Genitourinary Syndrome of Menopause: an Ongoing Observational Cohort Study

Genitourinary syndrome of menopause is a common condition that can affect women after the menopause. It may cause vaginal dryness, soreness, pain during sex, urinary symptoms and a reduced quality of life. Standard treatments include vaginal moisturisers, lubricants and vaginal oestrogen. Some women do not respond fully to these treatments, cannot use oestrogen, or prefer an alternative option.

This study will look at outcomes following treatment with MonaLisa Touch, a fractional carbon dioxide laser treatment. "Fractional carbon dioxide laser" means that a medical laser is used to deliver small, controlled areas of heat to the vaginal tissue. The aim is to stimulate healing and improve symptoms. This study will not test a new treatment or change the patient's usual care. It will observe patients who are already receiving MonaLisa Touch treatment as part of routine clinical practice.

The main question is whether patients report improvement in their symptoms and quality of life after treatment, and whether any side effects or complications occur. The study will also help doctors and patients better understand longer-term outcomes following treatment.

Participants will be women with symptoms of genitourinary syndrome of menopause who are being considered for, or are receiving, MonaLisa Touch treatment. Participation will involve giving consent for information about their symptoms, treatment and follow-up to be collected and analysed. This may include questionnaires before and after treatment. Taking part is voluntary and will not affect the care offered.

The study will be conducted in a private clinical setting at Clarendon Health. It is expected to run as an ongoing observational study, with participants followed up after treatment as part of routine care.

The research is funded by Clarendon Health and no personal identifying information will be included in published results.

Studieoversikt

Status

Har ikke rekruttert ennå

Studietype

Observasjonsmessig

Registrering (Antatt)

100

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

35 år til 90 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

Women with symptoms consistent with genitourinary syndrome of menopause. These may include vaginal dryness, soreness, irritation, pain during sex, urinary symptoms, recurrent urinary symptoms, or related symptoms affecting quality of life.

Beskrivelse

Inclusion Criteria:

Women aged 35 years or over.

Women with symptoms consistent with genitourinary syndrome of menopause (GSM), including vaginal dryness, soreness, irritation, pain during sexual intercourse, urinary symptoms, or related symptoms affecting quality of life.

Women who are perimenopausal or postmenopausal, or who have menopause-related symptoms associated with premature ovarian insufficiency, early menopause, surgical menopause, medically induced menopause, or treatment-related oestrogen deficiency.

Women with menopause-related symptoms following breast cancer or other cancer treatments, including those receiving oestrogen-blocking treatments such as aromatase inhibitors or tamoxifen, may be included where clinically appropriate.

Women who are being considered for, or are receiving, MonaLisa Touch fractional carbon dioxide laser treatment as part of routine clinical care.

Women who are able to understand the study information and provide informed consent.

Women who are willing for relevant clinical information, treatment details, follow-up information and outcomes to be collected and analysed for research purposes.

Women who are willing to complete patient-reported outcome questionnaires before and after treatment, where applicable.

Women who agree to the review of relevant clinical records, including treatment details, additional therapies, follow-up findings and reported adverse events.

Exclusion Criteria:

  • Women under 35 years of age.

Women without symptoms consistent with genitourinary syndrome of menopause or menopause-related oestrogen deficiency.

Women considered unsuitable for MonaLisa Touch fractional carbon dioxide laser treatment following clinical assessment.

Women with active or suspected genital, vaginal, urinary or pelvic infection requiring investigation or treatment before laser therapy.

Women with unexplained vaginal bleeding that has not been appropriately investigated.

Women with suspected or confirmed gynaecological malignancy requiring further investigation or treatment before laser therapy.

Women who are pregnant.

Women who are unable to understand the study information or provide informed consent.

Women who do not consent to the use of their clinical information or patient-reported outcomes for research purposes.

Women who are unable or unwilling to complete the required study questionnaires or follow-up assessments.

Women for whom the treating clinician considers study participation inappropriate because of clinical risks, safeguarding concerns or other relevant circumstances

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in overall GSM symptom severity using a predefined composite 0-10 score
Tidsramme: 4 years

Overall genitourinary syndrome of menopause (GSM) symptom severity will be assessed using a study-specific, non-validated numerical rating scale covering five symptom domains: vaginal dryness, burning or soreness, itching or irritation, pain during intercourse, and urinary symptom severity. Each domain is scored from 0 (no symptoms) to 10 (worst imaginable symptoms).

The composite score is the mean of the applicable domain scores, ranging from 0 to 10, with higher scores indicating worse symptoms. At least four domains must have valid baseline and follow-up scores. The same domains will be used at both assessments. Non-applicable or missing responses are excluded; no values will be imputed.

Change is calculated as follow-up minus baseline composite score. Negative values indicate improvement.

4 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Vaginal Health Index (VHI)
Tidsramme: 4 years

Vaginal health will be assessed using the Vaginal Health Index (VHI), a clinician-assessed measure evaluating five parameters: vaginal elasticity, vaginal fluid volume, vaginal pH, epithelial integrity and vaginal moisture.

Each parameter is scored from 1 to 5, producing a total score ranging from 5 to 25. Higher scores indicate better vaginal health.

The change in VHI score will be calculated by subtracting the baseline score from the follow-up score. Positive values indicate improvement in vaginal health, while negative values indicate deterioration.

VHI scores will be compared before and after MonaLisa Touch fractional carbon dioxide laser treatment to assess changes in vaginal tissue health over time.

4 years
How do outcomes vary between patients, including those who use MonaLisa Touch treatment alone and those who also use other treatments, such as vaginal oestrogen?
Tidsramme: 4 years

Changes in overall genitourinary syndrome of menopause (GSM) symptom severity will be compared between participants receiving MonaLisa Touch fractional carbon dioxide laser treatment alone and those receiving MonaLisa Touch alongside additional treatments, such as vaginal oestrogen.

Symptom severity will be assessed using the study-specific composite numerical rating scale, ranging from 0 (no symptoms) to 10 (worst imaginable symptoms), as defined in the primary outcome measure.

For each participant, change in symptom severity will be calculated by subtracting the baseline composite score from the follow-up score. The mean change in each treatment group will then be calculated, and the difference in mean change between groups will be reported.

Negative changes indicate symptom improvement. This comparison will be exploratory, as treatment allocation is not randomised and differences between groups may be influenced by patient characteristics and other treatments.

4 years
Change in Female Sexual Function Index (FSFI)
Tidsramme: 4 years

Sexual function will be assessed using the validated 19-item Female Sexual Function Index (FSFI), a patient-reported questionnaire evaluating six domains: sexual desire, arousal, lubrication, orgasm, satisfaction and pain.

Domain scores are calculated using the standard FSFI scoring method and combined to produce a total score ranging from 2 to 36, with higher scores indicating better sexual function.

Change in sexual function will be calculated by subtracting the baseline FSFI total score from the follow-up score. Positive values indicate improvement in sexual function, while negative values indicate deterioration.

FSFI scores will be assessed before and after MonaLisa Touch fractional carbon dioxide laser treatment to evaluate changes in sexual function over time. Results will be interpreted with consideration of participants' sexual activity status.

4 years
Number of participants experiencing adverse events or complications
Tidsramme: 4 years

The number of participants experiencing one or more adverse events, side effects or complications following MonaLisa Touch fractional carbon dioxide laser treatment will be recorded throughout the study follow-up period.

Adverse events may include vaginal discomfort, pain, bleeding, discharge, infection, urinary symptoms or other unexpected effects reported following treatment.

Events will be recorded according to their nature, severity, duration, outcome and possible relationship to treatment. Serious adverse events will be identified and documented separately.

The number and percentage of participants experiencing at least one adverse event will be reported, together with a summary of the types and severity of events observed.

4 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

1. oktober 2030

Studiet fullført (Antatt)

1. oktober 2031

Datoer for studieregistrering

Først innsendt

24. september 2026

Først innsendt som oppfylte QC-kriteriene

16. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • CH-MLT-GSM-OBS-001

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere